Stockscreener 앱 받기
1.32
5.60%
0.07
시간 외 거래:
1.29
-0.03
-2.27%
Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April - Defense World
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News
Understanding the Risks of Investing in Galmed Pharmaceuticals Ltd (GLMD) - knoxdaily.com
Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (GLMD) Collaborates with VCU to Tackle GI Cancer Drug Resistance - GuruFocus
GLMD’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Understanding GLMD stock ratios for better investment decisions - uspostnews.com
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
Is Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Stock Worth Investing In for High Returns? - Marketing Sentinel
Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up - marketscreener.com
Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development - Stocks Telegraph
Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks
Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus
Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation - marketscreener.com
Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed partners with VCU to target drug resistance - The Pharma Letter
Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks
Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire
Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks
Galmed reports key biomarkers for heart and liver health - Investing.com
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Kilgore News Herald
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire
Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.32 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.32 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 - Yahoo Finance
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Phar stock hits 52-week low at $1.66 amid challenges - Investing.com India
Galmed Phar stock hits 52-week low at $1.66 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals Secures New Patent for NASH Therapy - TipRanks
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy - PR Newswire
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
Can Galmed Pharmaceuticals Ltd (GLMD) meet market expectations this quarter? - uspostnews.com
Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa
0.39%
3.66%
자본화:
|
볼륨(24시간):